Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard A Fine

Showing results (161-170 of 168) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 168 results.
Acta Neuropathologica Communications|November 21, 2013
The influence of DNA repair on neurological degeneration, cachexia, skin cancer and internal neoplasms: autopsy report of four xeroderma pigmentosum patients (XP-A, XP-C and XP-D)Jin-Ping Lai, Yen-Chun Liu, Meghna Alimchandani, et al.
Neuro-Oncology|March 22, 2008
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomasKathleen R Lamborn, W K Alfred Yung, Susan M Chang, et al.
Neuro-Oncology|March 19, 2009
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, et al.
Cancer Cell|July 14, 2023
Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodelingHye-Min Jeon, Jeong-Yub Kim, Hee Jin Cho, et al.
Cell Reports|January 21, 2014
ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell stateYakov Chudnovsky, Dohoon Kim, Siyuan Zheng, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 1, 2005
Central nervous system cancers: Clinical Practice Guidelines in OncologySteven S Brem, Philip J Bierman, Peter Black, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, et al.
Cancer Discovery|May 17, 2012
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitorsIgor Vivanco, H Ian Robins, Daniel Rohle, et al.
Pageof 17

Showing results (161-170 of 168) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 168 results.
Acta Neuropathologica Communications|November 21, 2013
The influence of DNA repair on neurological degeneration, cachexia, skin cancer and internal neoplasms: autopsy report of four xeroderma pigmentosum patients (XP-A, XP-C and XP-D)Jin-Ping Lai, Yen-Chun Liu, Meghna Alimchandani, et al.
Neuro-Oncology|March 22, 2008
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomasKathleen R Lamborn, W K Alfred Yung, Susan M Chang, et al.
Neuro-Oncology|March 19, 2009
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, et al.
Cancer Cell|July 14, 2023
Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodelingHye-Min Jeon, Jeong-Yub Kim, Hee Jin Cho, et al.
Cell Reports|January 21, 2014
ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell stateYakov Chudnovsky, Dohoon Kim, Siyuan Zheng, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 1, 2005
Central nervous system cancers: Clinical Practice Guidelines in OncologySteven S Brem, Philip J Bierman, Peter Black, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, et al.
Cancer Discovery|May 17, 2012
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitorsIgor Vivanco, H Ian Robins, Daniel Rohle, et al.
Pageof 17